स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

azacitidin - prašek za suspenzijo za injiciranje - azacitidin 100 mg / 1 viala - azacitidin

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine betapharm je indiciran za zdravljenje odraslih bolnikih, ki niso primerni za haematopoietic stem cell presaditev (hsct) z:vmesne-2 in visokim tveganjem myelodysplastic sindromov (mds) je v skladu z mednarodnim prognostic sistem točkovanja (ipss),kronične myelomonocytic levkemijo (cmml) z 10 % na 29 % mozga eksplozije brez myeloproliferative motnje,akutno mieloično levkemijo (aml) z 20 % do 30 % blastov in multi-rodbine displazija, po ocenah svetovne zdravstvene organizacije (who) razvrstitev,aml s > 30 % mozgu eksplozije glede na razvrstitev, ki.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine soglasju je indicirano za zdravljenje odraslih bolnikih, ki niso primerni za haematopoietic stem cell presaditev (hsct) z:- intermediate-2 in visokim tveganjem myelodysplastic sindromov (mds) je v skladu z mednarodnim prognostic sistem točkovanja (ipss),- kronično myelomonocytic levkemijo (cmml) z 10-29 % mozga eksplozije brez myeloproliferative motnje,- akutno mieloično levkemijo (aml) z 20-30 % blastov in multi-rodbine displazija, po ocenah svetovne zdravstvene organizacije (who), in razvrščanje,- aml s >30% mozgu eksplozije glede na razvrstitev, ki.

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zincum metallicum - kroglica - zincum metallicum 200 c / 1 g - -

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

zincum metallicum - kroglica - zincum metallicum 1 lm / 1 g - -

स्लोवेनिया - स्लोवेनियाई - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

generics (uk) ltd. - imatinib - filmsko obložena tableta - imatinib 400 mg / 1 tableta - imatinib

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - insulin human - insulins in analogov za injiciranje, vmesne-deluje - cats; dogs - za zdravljenje sladkorne bolezni pri mačkah in psih doseči zmanjšanje hyperglycaemia in izboljšanje povezane klinične znake.

यूरोपीय संघ - स्लोवेनियाई - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.